Bharat Biotech’s COVAXIN, India’s first indigenous vaccine against coronavirus.The World Health Organisation (WHO) on Tuesday (5 October) said that it will take a decision on granting Emergency Use Listing (EUL) to Bharat Biotech's Covaxin next week.
"WHO and an independent group of experts are scheduled to meet next week to carry out the risk, benefit assessment and come to a final decision whether to grant Emergency Use Listing to Covaxin," the global health body said in a tweet.
The WHO added that Bharat Biotech has been submitting data to it on a rolling basis and provided additional information at its request on 27 September.
"WHO experts are currently reviewing this info and if it addresses all questions raised, WHO assessment will be finalised next week," the global health body said.
It further added that the "Emergency Use Listing process - done by WHO and the Technical Advisory Group of independent experts - is centred on determining if a manufactured product (e.g. a vaccine) is quality-assured, safe and effective".
Hyderabad-based Bharat Biotech had recently made a presentation of the safety and efficacy data on its vaccine to the strategic advisory group of experts on immunization (SAGE), an expert body that advises the WHO, reports Economic Times.
An Appeal...
Dear Reader,
As you are no doubt aware, Swarajya is a media product that is directly dependent on support from its readers in the form of subscriptions. We do not have the muscle and backing of a large media conglomerate nor are we playing for the large advertisement sweep-stake.
Our business model is you and your subscription. And in challenging times like these, we need your support now more than ever.
We deliver over 10 - 15 high quality articles with expert insights and views. From 7AM in the morning to 10PM late night we operate to ensure you, the reader, get to see what is just right.
Becoming a Patron or a subscriber for as little as Rs 1200/year is the best way you can support our efforts.